Blog
RSS FeedPosted by Michael Wonder on 30 Mar 2025
Bristol Myers Squibb receives positive CHMP opinion for peri-operative regimen of neo-adjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer in patients with tumour cell PD-L1 expression ≥1%
28 March 2025 - Recommendation based on Phase 3 CheckMate -77T trial showing significant event-free survival improvement when compared to neoadjuvant ...
Posted by Michael Wonder on 29 Mar 2025
FDA approves durvalumab for muscle invasive bladder cancer
28 March 2025 - Today, the FDA approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neo-adjuvant treatment, followed by ...
Posted by Michael Wonder on 27 Mar 2025
FDA approves cabozantinib for adults and paediatric patients 12 years of age and older with pNET and epNET
26 March 2025 - Today, the FDA approved cabozantinib (Cabometyx, Exelixis) for adult and paediatric patients 12 years of age ...
Posted by Michael Wonder on 24 Mar 2025
CStone submits application to the EMA for new indication of sugemalimab in stage III non-small cell lung cancer
23 March 2025 - CStone Pharmaceuticals today announced the submission of a type II variation application to the EMA for sugemalimab. ...
Posted by Michael Wonder on 20 Mar 2025
FDA approves pembrolizumab for HER2 positive gastric or gastro-oesophageal junction adenocarcinoma expressing PD-L1
19 March 2025 - Today, the FDA granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy ...
Posted by Michael Wonder on 20 Mar 2025
Azercabtagene zapreleucel granted FDA fast track designation in blood cancer DLBCL
19 March 2025 - Imugene is pleased to announce that the US FDA has granted fast track designation to its ...
Posted by Michael Wonder on 20 Mar 2025
Health Canada approves Keytruda for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy
19 March 2025 - Approval is based on the Phase 3 KEYNOTE-868/NRG-GY018 trial. ...
Posted by Michael Wonder on 17 Mar 2025
Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer
17 March 2025 - Approval based on ADRIATIC Phase 3 trial results which showed a 27% reduction in the risk ...
Posted by Michael Wonder on 17 Mar 2025
Bristol Myers Squibb receives approval from the European Commission to expand use of CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma
14 March 2025 - In the TRANSCEND FL trial, 97.1% of patients responded to Breyanzi , with 94.2% of patients achieving ...
Posted by Michael Wonder on 12 Mar 2025
PHARMAC to fund more cancer medicines (March 2025)
12 March 2025 - PHARMAC is funding six more medicines for cancers and one for antibiotic resistant infections. ...
Posted by Michael Wonder on 12 Mar 2025
Atezolizumab for the first-line treatment of adults with advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable
12 March 2025 - NICE is unable to make a recommendation on the use of atezolizumab (Tecentriq) in the NHS for ...
Posted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 11 Mar 2025
Health Canada authorises Lazcluze (lazertinib) in combination with Rybrevant (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
10 March 2025 - Phase 3 MARIPOSA study showed Lazcluze plus Rybrevant significantly improved progression-free survival, reducing the risk of ...
Posted by Michael Wonder on 08 Mar 2025
This immunotherapy drug helped me beat cancer - instead of $229k it now costs $31
8 March 2025 - When she was just 26-years-old, Bianca Tesoriero’s life changed in an instant, following a visit to her ...
Posted by Michael Wonder on 07 Mar 2025
Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma
7 March 2025 - Approval based on results of Phase 3 CheckMate-9DW clinical trial demonstrating a statistically significant and clinically ...